Evidence map›Paper›PMID 37236196›Full record

ArticleCancer cell2023

CDKN2A deletion remodels lipid metabolism to prime glioblastoma for ferroptosis.

Jenna K Minami, Danielle Morrow, Nicholas A Bayley, Elizabeth G Fernandez, Jennifer J Salinas, Christopher Tse, Henan Zhu, Baolong Su, Rhea Plawat, Anthony Jones and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer cell, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 133 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
133citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

133 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Ferroptosis in cancer: molecular mechanisms, biological roles, and therapeutic significance.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review

73 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Jenna K MinamiDepartment of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA 90095, USA.
Danielle MorrowDepartment of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA 90095, USA.
Nicholas A BayleyDepartment of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA 90095, USA.
Elizabeth G FernandezDepartment of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA 90095, USA.
Jennifer J SalinasDepartment of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA 90095, USA.
Christopher TseDepartment of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA 90095, USA.
Henan ZhuDepartment of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA 90095, USA.
Baolong SuDepartment of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Rhea PlawatDepartment of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA 90095, USA.
Anthony JonesDepartment of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA 90095, USA.
Alessandro SammarcoDepartment of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Linda M LiauDepartment of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
Thomas G GraeberDepartment of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA 90095, USA; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
Kevin J WilliamsUCLA Lipidomics Core, University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Biological Chemistry, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Timothy F CloughesyDepartment of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA 90095, USA; Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
Scott J DixonDepartment of Biology, Stanford University, Stanford, CA 94305, USA. Electronic address: sjdixon@stanford.edu.
Steven J BensingerDepartment of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA 90095, USA; Department of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA; UCLA Lipidomics Core, University of California, Los Angeles, Los Angeles, CA 90095, USA; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA. Electronic address: sbensinger@mednet.ucla.edu.
David A NathansonDepartment of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA 90095, USA; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA. Electronic address: dnathanson@mednet.ucla.edu.

Funding

UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Linda M Liau · 2017 to 2026
$25.2M
Understanding the Influence of Lipid Homeostasis on T cell FunctionP01HL146358 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI FONG, LOREN GI · 2019 to 2023
$11.7M
Mammalian models for integrated metabolic and molecular profiling of malignant gliomaR01CA227089 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GRAEBER, THOMAS G, NATHANSON, DAVID A. · 2018 to 2022
$2.7M
CDKN2A couples lipid metabolism to ferroptosis in glioblastomaR01NS121319 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BENSINGER, STEVEN J, DIXON, SCOTT · 2021 to 2025
$2.5M
Quantitative molecular MR-PET imaging of glycolysis in glioblastomaR01CA279984 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Benjamin M. Ellingson, David A. Nathanson · 2023 to 2026
$2.4M
NCI NIH HHS P50 CA211015NCI NIH HHS R01 CA227089NCI NIH HHS R01 CA279984NHLBI NIH HHS P01 HL146358NINDS NIH HHS R01 NS121319
6 · The paper itself

Abstract

Malignant tumors exhibit heterogeneous metabolic reprogramming, hindering the identification of translatable vulnerabilities for metabolism-targeted therapy. How molecular alterations in tumors promote metabolic diversity and distinct targetable dependencies remains poorly defined. Here we create a resource consisting of lipidomic, transcriptomic, and genomic data from 156 molecularly diverse glioblastoma (GBM) tumors and derivative models. Through integrated analysis of the GBM lipidome with molecular datasets, we identify CDKN2A deletion remodels the GBM lipidome, notably redistributing oxidizable polyunsaturated fatty acids into distinct lipid compartments. Consequently, CDKN2A-deleted GBMs display higher lipid peroxidation, selectively priming tumors for ferroptosis. Together, this study presents a molecular and lipidomic resource of clinical and preclinical GBM specimens, which we leverage to detect a therapeutically exploitable link between a recurring molecular lesion and altered lipid metabolism in GBM.

Indexed as

FerroptosisGlioblastomaLipid MetabolismCyclin-Dependent Kinase Inhibitor p16Gene Expression ProfilingHumansNeoplasm Recurrence, LocalCDKN2A protein, humanCyclin-Dependent Kinase Inhibitor p16CDKN2AferroptosisglioblastomaGPX4lipid dropletlipid peroxidationRNA sequencingshotgun lipidomicstriacylglyceride

Identifiers

PMID37236196
PMCPMC10330677

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.